Assyro AI

Orange Book product · Brand (NDA)

VABOMERE

MEROPENEM; VABORBACTAM

Brand (NDA)NDA 209776RX REMPEX

At a glance

Aug 29, 2017

Approved

Brand (NDA)

Application

Not listed

TE code

10

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Aug 29, 2017

    8 yr 11 mo ago

  2. Exclusivity ends · NCE

    New chemical entity exclusivity (5 years)

    Aug 29, 2022

    3 yr 10 mo ago

  3. Today

  4. Exclusivity ends · GAIN

    Qualified infectious disease product exclusivity (adds 5 years)

    Aug 29, 2027

    in 1 yr 3 mo

  5. Patent 10172874 expires

    Listed drug product patent expiration.

    Aug 08, 2031

    in 5 yr 3 mo

  6. Patent 10183034 expires

    Listed method-of-use patent (U-2490) expiration.

    Aug 08, 2031

    in 5 yr 3 mo

  7. Patent 10561675 expires

    Listed method-of-use patent (U-2490) expiration.

    Aug 08, 2031

    in 5 yr 3 mo

  8. Patent 11007206 expires

    Listed method-of-use patent (U-3128) expiration.

    Aug 08, 2031

    in 5 yr 3 mo

  9. Patent 12171772 expires

    Listed drug substance patent expiration.

    Aug 08, 2031

    in 5 yr 3 mo

  10. Patent 9694025 expires

    Listed method-of-use patent (U-2120) expiration.

    Aug 08, 2031

    in 5 yr 3 mo

  11. Patent 8680136 expires

    Listed drug substance patent expiration.

    Aug 29, 2031

    in 5 yr 3 mo

  12. Patent 12478606 expires

    Listed method-of-use patent (U-3421) expiration.

    Jan 08, 2038

    in 11 yr 9 mo

  13. Patent 11376237 expires

    Listed method-of-use patent (U-3421) expiration.

    Apr 06, 2039

    in 13 yr

  14. Patent 12533342 expires

    Listed method-of-use patent (U-3421) expiration.

    May 20, 2039

    in 13 yr 1 mo

Pharmaceutical detail

Active ingredient

MEROPENEM; VABORBACTAM

Strength

1GM/VIAL;1GM/VIAL

Dosage form

POWDER

Route

INTRAVENOUS

TE code

Not listed

Application

NDA 209776

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

  • NCENew chemical entity exclusivity (5 years)

    Aug 29, 2022

    3 yr 10 mo ago

  • GAINQualified infectious disease product exclusivity (adds 5 years)

    Aug 29, 2027

    in 1 yr 3 mo

Listed patents (10)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10172874Aug 08, 2031in 5 yr 3 mo
Product
10183034Aug 08, 2031in 5 yr 3 mo
U-2490
10561675Aug 08, 2031in 5 yr 3 mo
U-2490
11007206Aug 08, 2031in 5 yr 3 mo
U-3128
12171772Aug 08, 2031in 5 yr 3 mo
Substance
9694025Aug 08, 2031in 5 yr 3 mo
U-2120
8680136Aug 29, 2031in 5 yr 3 mo
SubstanceProduct
12478606Jan 08, 2038in 11 yr 9 mo
U-3421
11376237Apr 06, 2039in 13 yr
U-3421
12533342May 20, 2039in 13 yr 1 mo
U-3421
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.